Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WSB1 | SNV | Missense_Mutation | novel | c.883G>T | p.Gly295Trp | p.G295W | Q9Y6I7 | protein_coding | tolerated(0.1) | probably_damaging(0.998) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
WSB1 | SNV | Missense_Mutation | novel | c.361N>C | p.Glu121Gln | p.E121Q | Q9Y6I7 | protein_coding | tolerated(0.18) | benign(0.229) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
WSB1 | SNV | Missense_Mutation | | c.953N>A | p.Ser318Tyr | p.S318Y | Q9Y6I7 | protein_coding | tolerated(0.13) | possibly_damaging(0.876) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
WSB1 | SNV | Missense_Mutation | novel | c.1021G>A | p.Asp341Asn | p.D341N | Q9Y6I7 | protein_coding | tolerated(0.07) | benign(0.005) | TCGA-EW-A6SB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WSB1 | SNV | Missense_Mutation | | c.572G>C | p.Arg191Thr | p.R191T | Q9Y6I7 | protein_coding | deleterious(0.05) | benign(0.114) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
WSB1 | SNV | Missense_Mutation | rs780700572 | c.1103C>T | p.Ala368Val | p.A368V | Q9Y6I7 | protein_coding | tolerated(0.1) | benign(0.228) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
WSB1 | SNV | Missense_Mutation | | c.257N>C | p.Leu86Ser | p.L86S | Q9Y6I7 | protein_coding | tolerated(0.82) | possibly_damaging(0.69) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
WSB1 | SNV | Missense_Mutation | | c.341N>T | p.Ala114Val | p.A114V | Q9Y6I7 | protein_coding | deleterious(0) | possibly_damaging(0.575) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
WSB1 | SNV | Missense_Mutation | novel | c.595N>A | p.Asp199Asn | p.D199N | Q9Y6I7 | protein_coding | deleterious(0.01) | possibly_damaging(0.492) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
WSB1 | SNV | Missense_Mutation | rs773398485 | c.103N>T | p.Arg35Cys | p.R35C | Q9Y6I7 | protein_coding | tolerated(0.18) | benign(0) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |